PTGX

Protagonist Therapeutics Inc

PTGX.US protagonist-inc.com + Research + Basket
CIK 0001377121
Employees 141
Phone 510 474 0170
Fiscal year end December
IPO Aug 11, 2016
Address 7707 Gateway Boulevard, Newark, CA, United States, 94560
141.79
+0.67 (+0.47%)
USD · NASDAQ
52-week range
75.44
160.81
Trading at 78% of the 52-week range
Market Cap
9.08B
P/E Ratio
136.23
Forward P/E
36.90
Book Value
13.01
Div. Yield
N/A
% Institutions
119.73%
% Insiders
0.709%

1 Year

+87.5%

3 Year

+888.2%

10 Year

+650.6%
Description

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Actions

Add an action for PTGX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Dinesh V. Patel Ph.D. CEO, President, Secretary & Director 1957
Mr. Asif Ali Executive VP & CFO 1974
Dr. Arturo M. Molina FACP, M.D., M.S. Chief Medical Officer 1959
Mr. Venkat Thalladi Ph.D. EVP & Chief Technical Officer NA
Dr. Newman Yeilding M.D. Executive VP, Chief Scientific Officer NA
Mr. Matthew M. Gosling J.D. Executive VP and Chief Legal & Business Officer 1971
Ms. Carena Spivey Executive VP & Chief Human Resources Officer NA
Dr. Ashok Bhandari Ph.D. EVP & Chief Discovery Officer 1964
Mr. Carter J. King Executive Vice President of Business Development 1971
Ms. Abha Bommireddi Executive VP & Chief of Staff NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 20, 2026 Asif Ali N/A Sale 1.75K $105.47 $184.57K SEC
Mar 26, 2026 Arturo Md Molina N/A Sale 15.00K $104.79 $1.57M SEC
Mar 26, 2026 Asif Ali N/A Sale 24.77K $104.24 $2.58M SEC
Mar 26, 2026 Harold E Selick N/A Sale 24.00K $105.00 $2.52M SEC
Mar 25, 2026 Dinesh V Ph D Patel N/A Sale 54.64K $101.00 $5.52M SEC
Mar 24, 2026 Dinesh V Ph D Patel N/A Sale 59.00 $101.00 $5.96K SEC
Feb 17, 2026 Lewis T Williams N/A Sale 18.00K $82.42 $1.48M SEC
Feb 06, 2026 William D Waddill N/A Sale 20.00K $83.68 $1.67M SEC
Jan 27, 2026 Arturo Md Molina N/A Sale 5.00K $82.00 $410.00K SEC
Jan 27, 2026 Asif Ali N/A Sale 46.20K $83.13 $3.84M SEC
Jan 27, 2026 Dinesh V Ph D Patel N/A Sale 4.07K $83.19 $338.42K SEC
Jan 26, 2026 Dinesh V Ph D Patel N/A Sale 24.89K $84.03 $2.09M SEC
Jan 23, 2026 Arturo Md Molina N/A Sale 13.15K $82.42 $1.08M SEC
Jan 23, 2026 Dinesh V Ph D Patel N/A Sale 19.32K $84.59 $1.63M SEC
Jan 20, 2026 Arturo Md Molina N/A Sale 9.51K $82.48 $784.71K SEC
Jan 20, 2026 Asif Ali N/A Sale 8.59K $82.48 $708.34K SEC
Jan 20, 2026 Dinesh V Ph D Patel N/A Sale 34.44K $82.48 $2.84M SEC
Oct 10, 2025 William D Waddill N/A Sale 12.00K $81.62 $979.44K SEC
Sep 22, 2025 William D Waddill N/A Sale 4.00K $64.25 $257.00K SEC
Aug 27, 2025 William D Waddill N/A Sale 4.00K $59.25 $237.00K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 10.31M Jun 30, 2026 15.93% $0.02 5.40%
Farallon Capital Management, L.L.C. 6.35M Jun 30, 2026 9.81% $3.59 0.00%
RTW INVESTMENTS, LLC 5.06M Jun 30, 2026 7.82% $5.30 0.04%
Vanguard Portfolio Management, LLC 3.63M Jun 30, 2026 5.61% $0.02 4.25%
Wellington Management Company LLP 3.42M Jun 30, 2026 5.28% $0.07 -5.08%
UBS Group AG 3.40M Jun 30, 2026 5.25% $0.05 -34.35%
State Street Corp 3.32M Jun 30, 2026 5.13% $0.01 6.57%
HHG PLC 2.89M Mar 31, 2026 4.47% $0.15 9.12%
Vanguard Capital Management, LLC 2.85M Jun 30, 2026 4.41% $0.01 1.69%
Johnson & Johnson 2.45M Jun 30, 2026 3.79% $37.59 0.00%
Amvescap Plc. 2.34M Jun 30, 2026 3.62% $0.02 8.13%
T. Rowe Price Associates, Inc. 2.15M Jun 30, 2026 3.32% $0.03 29.07%
Jupiter Topco LLC 2.13M Jun 30, 2026 3.29% $0.11 0.00%
Geode Capital Management, LLC 1.74M Jun 30, 2026 2.69% $0.01 4.30%
Woodline Partners LP 1.41M Jun 30, 2026 2.19% $0.54 0.00%
Bank of America Corp 1.32M Jun 30, 2026 2.05% $0.01 2.24%
Jennison Associates LLC 1.15M Jun 30, 2026 1.78% $0.08 7.43%
Perceptive Advisors LLC 981.88K Jun 30, 2026 1.52% $1.81 -20.23%
ADAR1 Capital Management LLC 960.86K Jun 30, 2026 1.48% $5.39 -3.35%
Morgan Stanley - Brokerage Accounts 905.99K Jun 30, 2026 1.40% $0.01 -11.02%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 3.85M 5.96% ▲ 0.02% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.05M 3.17% ▲ 0.01% Sep 30, 2026
3 iShares Russell 2000 ETF 1.59M 2.46% ▼ 0.93% Sep 30, 2026
4 Vanguard Small Cap Index 1.46M 2.25% ▼ 1.63% Sep 30, 2026
5 Vanguard Health Care Inv 1.38M 2.13% ▼ 11.40% Jun 30, 2026
6 State Street® SPDR® S&P® Biotech ETF 1.02M 1.58% ▼ 1.87% Sep 30, 2026
7 Vanguard MStar Small Cap Growth Indx Inv 811.16K 1.25% ▼ 4.48% Sep 30, 2026
8 Invesco Discovery A 806.35K 1.25% ▼ 5.03% Aug 31, 2026
9 Fidelity Small Cap Index 672.66K 1.04% ▲ 0.85% Jul 31, 2026
10 Fidelity Select Biotechnology 607.71K 0.94% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $9.08B
EBITDA: $59.88M
P/E Ratio: $136.23
PEG Ratio: $0.00
Book Value: $13.01
Earnings/Share: $1.03
Profit Margin: 29.40%
Operating Margin: 74.37%
ROA (TTM): 4.55%
ROE (TTM): 10.99%
Revenue (TTM): $281.99M
Revenue/Share (TTM): $4.36
Earnings Growth (YOY): 351.30%
Revenue Growth (YOY): 3,749.20%

Valuation Metrics

Enterprise Value: $8.18B
Trailing P/E: 136.23
Forward P/E: 36.90

Shares Statistics

Shares Outstanding: 64.71M
Shares Float: 52.89M
% Insiders: 0.709%
% Institutions: 119.73%
Short % Float: 16.78%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$46.02M
Cost of Goods Sold
adjust
$-1.23M
Gross Profit
subtotal
$44.79M
SG&A
adjust
$-44.85M
R&D
adjust
$-159.29M
Operating Income
subtotal
$-158.13M
Other / Non-Operating Items
adjust
$27.98M
Net Income
subtotal
$-130.15M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PTGX.US!